Neoadjuvant Pertuzumab Biosimilar Plus Trastuzumab/Docetaxel Meets pCR End Point in HER2+ Breast Cancer
HLX11—a pertuzumab biosimilar—plus trastuzumab/docetaxel met the pCR end point in a phase 3 trial in early or locally advanced HER2-positive breast cancer.